Clinical Trials Directory

Trials / Completed

CompletedNCT03475823

Cognitive and Blood Flow Effects of Mountain Tea

The Acute and Chronic Cognitive and Cerebral Blood Flow Effects of a Sideritis Scardica (Mountain Tea) Extract: a Double Blind, Randomized, Placebo Controlled, Parallel Groups Study in Healthy Humans

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
155 (actual)
Sponsor
Northumbria University · Academic / Other
Sex
All
Age
50 Years – 70 Years
Healthy volunteers
Accepted

Summary

Two doses (475 mg and 950 mg) of Sideritis Scardica (SS or 'mountain tea') are investigated for cognitive, mood, blood pressure and cerebral blood flow effects in a healthy group of 50-70 yr olds, both acutely and following 28 days of consumption.

Detailed description

The presence of polyphenols such as ferulic acid, chlorogenic acid and apigenin in Sideritis Scardica (SS or 'mountain tea') are likely responsible for the cognitive and mood effects of its consumption and this could be underpinned by the ability of such polyphenols to prevent monoamine neurotransmitter reuptake and to increase cerebral blood flow (CBF). The current randomised, placebo controlled, parallel groups study extends on the abovementioned small amount of literature; assessing both cognitive and mood outcomes in a sample of older (50-70 yrs) adults, as well as blood pressure (BP) and CBF, in a sub-sample, utilizing near-infrared spectroscopy (NIRS). The above will be assessed acutely (pre-dose and 90- and 310-mins post dose) on day 1 and following 28 days consumption of either a placebo control, and active control of 240 mg ginkgo biloba, 475 mg SS or 950 mg SS.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTSideritis ScardicaSideritis Scardica is a popular, naturally un-caffeinated Eastern European tea extract derived from the ironwort plant
DIETARY_SUPPLEMENTGinkgo bilobaGinkgo biloba is an extract from the ginkgo tree comprising ginkgolides and bilobalide. In this trial Ginkgo acted as an active control.
DIETARY_SUPPLEMENTPlacebo controlAn inert encapsulated powder provided by Finzelberg.

Timeline

Start date
2017-02-17
Primary completion
2017-09-18
Completion
2017-09-18
First posted
2018-03-23
Last updated
2018-03-23

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT03475823. Inclusion in this directory is not an endorsement.